Atai Life Sciences N.V. (ATAI)
Automate Your Wheel Strategy on ATAI
With Tiblio's Option Bot, you can configure your own wheel strategy including ATAI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ATAI
- Rev/Share 0.0117
- Book/Share 0.7322
- PB 8.1504
- Debt/Equity 0.0641
- CurrentRatio 4.0193
- ROIC -0.578
- MktCap 1276384553.0
- FreeCF/Share -0.411
- PFCF -15.7992
- PE -9.8114
- Debt/Assets 0.0487
- DivYield 0
- ROE -0.8562
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ATAI | Needham | -- | Buy | -- | $12 | Oct. 13, 2025 |
| Initiation | ATAI | Oppenheimer | -- | Outperform | -- | $14 | July 29, 2025 |
News
atai Life Sciences closes $149.5M public offering, extending cash runway into 2029
Published: October 21, 2025 by: Proactive Investors
Sentiment: Positive
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced the completion of a $149.5 million public offering of approximately 27 million common shares, including the full exercise of underwriters' option to purchase an additional 3.6 million shares at $5.48 per share. The financing included participation from both new and existing investors, such as Janus Henderson Investors, Foresite Capital, Deep Track Capital, HBM Partners, Ferring Ventures, Columbia Threadneedle Investments, Ally Bridge Group, Woodline Partners LP, and ADAR1 Capital Management.
Read More
atai Life Sciences (ATAI) Upgraded to Buy: Here's Why
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
atai Life Sciences (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Atai Life Sciences And Beckley Psytech: Promising Emerging Leader In Psychedelics
Published: October 20, 2025 by: Seeking Alpha
Sentiment: Positive
ATAI's main value driver is BPL-003. This candidate showed rapid and durable TRD benefits in its Phase 2b trials. BPL-003's 8 mg dose seemed to be ideal, which is why ATAI is going ahead with a Phase 3 with this dosing by Q2 2026. ATAI's broader pipeline includes VLS-01 DMT buccal film, EMP-01 R-MDMA for SAD, and other early-stage non-hallucinogenic 5-HT2A candidates.
Read More
Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upside
Published: October 13, 2025 by: Benzinga
Sentiment: Positive
Needham on Monday initiated coverage on Atai Life Sciences NV (NASDAQ:ATAI), a clinical-stage biopharmaceutical company focused on developing treatments for mental health.
Read More
Atai Life Sciences: Still A Decent Prospect - But Only Just
Published: October 01, 2025 by: Seeking Alpha
Sentiment: Positive
Atai Life Sciences N.V. has surged >275% YTD, driven by promising psychedelic drug candidates targeting treatment-resistant depression and other mental health disorders. ATAI's lead asset, BPL-003, shows strong, durable efficacy in early trials, potentially surpassing Spravato, but regulatory and scheduling hurdles remain significant risks. Despite a tight cash position and upcoming milestones, ATAI's valuation may be fair or slightly overvalued, with major catalysts like Phase 2b/3 data and FDA discussions ahead.
Read More
atai shares jump 10% on positive trial data for depression nasal spray
Published: September 23, 2025 by: Proactive Investors
Sentiment: Positive
Shares in atai Life Sciences (NASDAQ:ATAI, ETR:9VC) rose 10% on Tuesday after the company and its UK partner Beckley Psytech reported encouraging mid-stage trial results for their experimental nasal spray treatment for depression. The therapy, BPL-003, is a formulation of mebufotenin benzoate delivered via nasal spray.
Read More
Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year?
Published: September 19, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how atai Life Sciences N.V. (ATAI) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Read More
atai Life Sciences (ATAI) Upgraded to Buy: Here's What You Should Know
Published: September 11, 2025 by: Zacks Investment Research
Sentiment: Positive
atai Life Sciences (ATAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Here's Why atai Life Sciences (ATAI) Is a Great 'Buy the Bottom' Stock Now
Published: August 18, 2025 by: Zacks Investment Research
Sentiment: Positive
atai Life Sciences (ATAI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Read More
atai Life Sciences poised to lead treatment-resistant depression market with psychedelic candidate BPL-003
Published: July 23, 2025 by: Proactive Investors
Sentiment: Positive
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is gaining momentum in the psychedelics space, with Jefferies analysts highlighting the company's potential to leapfrog rival GH Research (NASDAQ:GHRS) and establish a leading position in the treatment-resistant depression (TRD) market with its intranasal 5-MeO-DMT candidate BPL-003. The analysts maintain a ‘Buy' rating and $7 price target on atai, about double the stock's price at the time of writing.
Read More
atai Life Sciences (ATAI) Upgraded to Strong Buy: Here's Why
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Positive
atai Life Sciences (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Read More
Spravato sales momentum underscores market potential for psychedelics, atai Life Sciences seen as key beneficiary
Published: July 18, 2025 by: Proactive Investors
Sentiment: Positive
Sales of Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray Spravato grew sequentially in the second quarter, marking a positive sign for the broader psychedelics sector, according to Jefferies analysts. Spravato sales grew 29% quarter-over-quarter to $414 million worldwide.
Read More
Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how atai Life Sciences N.V. (ATAI) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.
Read More
atai Life Sciences price target boosted on robust BPL-003 mid-stage trial results
Published: July 02, 2025 by: Proactive Investors
Sentiment: Positive
The atai Life Sciences (NASDAQ:ATAI, ETR:9VC) story has become more attractive following the release of robust Phase 2b trial results for BPL-003 in treatment-resistant depression, analysts at Jefferies believe. BPL-003, an intranasal formulation of DMT developed in partnership in Beckley Psytech, demonstrated rapid, robust and durable antidepressant effects with a single dose.
Read More
Atai: Critical Study Win Sets Up Double Approval Shot For Psychedelics In TRD
Published: July 02, 2025 by: Seeking Alpha
Sentiment: Positive
Atai Life Sciences' BPL-003 showed robust, rapid, and durable antidepressant effects in Phase 2b TRD data, spiking shares over 20%. BPL-003's short clinic time and strong efficacy could fit existing treatment paradigms, potentially rivaling J&J's Spravato if regulatory hurdles are cleared. Regulatory approval remains uncertain due to controlled substance scheduling, but Atai's differentiated pipeline and patent position offer significant long-term upside.
Read More
Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year?
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how atai Life Sciences N.V. (ATAI) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.
Read More
atai Life Sciences backed by positive sector readthrough from Compass Phase 3 data, analysts say
Published: June 23, 2025 by: Proactive Investors
Sentiment: Positive
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) remains a ‘Buy' for analysts at Jefferies, who continue to see significant upside ahead for the company following the release of new data from Compass Pathways (NASDAQ:CMPS)' late-stage trial of its synthetic psilocybin COMP360 in treatment-resistant depression (TRD). Compass Pathways on Monday reported that its COMP360 therapy reached its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in depression symptom severity compared to placebo.
Read More
FDA seen likely to grant emergency use authorizations for psychedelics, boosting sector stocks
Published: June 18, 2025 by: Proactive Investors
Sentiment: Positive
The Food and Drug Administration (FDA) may soon issue emergency use authorizations for psychedelic substances like psilocybin, proponents of psychedelic therapy believe, amid a shit in attitude towards psychedelic therapies under the Trump administration. Emergency use authorizations (EUAs) are considered a more likely near-term regulatory pathway for psychedelics such as psilocybin because, unlike full FDA approval, they require a lower standard of evidence, a report from health-oriented news website Stat published on Wednesday highlighted.
Read More
Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V.
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors?
Read More
Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how atai Life Sciences N.V. (ATAI) and Novartis (NVS) have performed compared to their sector so far this year.
Read More
atai Life Sciences gains maximum exposure to key psychedelic asset with Beckley Psytech merger
Published: June 02, 2025 by: Proactive Investors
Sentiment: Positive
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) stock is poised to move higher following its planned merger with Beckley Psytech, as the combined entity will provide investors with maximum exposure to a promising therapy targeting treatment-resistant depression (TRD), analysts at Jefferies believe. BPL-003, Beckley's intranasal formulation of 5-MeO-DMT, is a short-acting psychedelic with the potential to deliver rapid and durable effects in TRD.
Read More
atai Life Sciences and Beckley Psytech to merge in all-share deal, stock pops
Published: June 02, 2025 by: Proactive Investors
Sentiment: Positive
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) shares soared before Monday's opening bell after it announced it has inked a definitive agreement to merge with Beckley Psytech, a private clinical-stage biopharmaceutical company developing psychedelic-based therapies, in an all-share transaction valued at $390 million. The merger is contingent upon the achievement of pre-agreed success criteria in Beckley's ongoing Phase 2b trial of BPL-003 (mebufotenin benzoate), the company said.
Read More
atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK and BERLIN and OXFORD, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, and Beckley Psytech Limited (“Beckley”), a private clinical-stage biopharmaceutical company pioneering the next generation of mental health treatments, today announced a definitive agreement under which atai and Beckley plan to combine in an all-share transaction subject to pre-agreed BPL-003 (mebufotenin benzoate) Phase 2b success criteria.
Read More
atai Life Sciences N.V. (ATAI) Is Up 18.71% in One Week: What You Should Know
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors?
Read More
atai Life Sciences N.V. (ATAI) Just Flashed Golden Cross Signal: Do You Buy?
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Atai Life Sciences N.V. (ATAI) reached a significant support level, and could be a good pick for investors from a technical perspective.
Read More
Is atai Life Sciences (ATAI) Outperforming Other Medical Stocks This Year?
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how atai Life Sciences N.V. (ATAI) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Read More
atai Life Sciences upside highlighted by analysts as more positive data backs Beckley Psytech's depression therapy
Published: May 20, 2025 by: Proactive Investors
Sentiment: Positive
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) could see its stock more than double following the release of key trial data later in 2025, according to Jefferies analysts, following another batch of positive clinical trial results from Beckley Psytech's BPL-003 program targeting treatment-resistant depression (TRD). Beckley Psytech's Phase 2a study of BPL-003, an intranasal form of 5-MeO-DMT, showed that a single dose of the therapy along with selective serotonin reuptake inhibitor (SSRI) therapies, produced rapid, robust, and sustained antidepressant effects.
Read More
atai Life Sciences shares gain momentum ahead of pivotal trial readouts
Published: May 15, 2025 by: Proactive Investors
Sentiment: Positive
atai Life Sciences (NASDAQ:ATAI, ETR:9VC)' stock is poised to climb significantly, driven by a series of clinical catalysts this year and next, analysts at Jefferies wrote following the release of the company's first quarter results. The analysts repeated their ‘Buy' rating and $5 price target on atai, which traded up 11.8% at $1.60 on Thursday afternoon.
Read More
atai Life Sciences doses first patient in Phase 2 social anxiety trial
Published: May 13, 2025 by: Proactive Investors
Sentiment: Positive
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has dosed the first patient in its Phase 2 clinical trial of EMP-01 for the treatment of social anxiety disorder (SAD). EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine, is being investigated in an exploratory, randomized, double-blind, placebo-controlled study involving approximately 60 adult participants with SAD.
Read More
atai Life Sciences doses first patient in Phase 2 social anxiety trial
Published: May 13, 2025 by: Proactive Investors
Sentiment: Positive
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has dosed the first patient in its Phase 2 clinical trial of EMP-01 for the treatment of social anxiety disorder (SAD). EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine, is being investigated in an exploratory, randomized, double-blind, placebo-controlled study involving approximately 60 adult participants with SAD.
Read More
About Atai Life Sciences N.V. (ATAI)
- IPO Date 2021-06-18
- Website https://www.atai.life
- Industry Biotechnology
- CEO Srinivas G. Rao
- Employees 54